• / Free eNewsletters & Magazine
  • / My Account
Home>Acute Decompensated Heart Failure Forecast in 12 Major Markets 2017-2027 - Research and Markets

Acute Decompensated Heart Failure Forecast in 12 Major Markets 2017-2027 - Research and Markets

Acute Decompensated Heart Failure Forecast in 12 Major Markets 2017-2027 - Research and Markets

10/02/2017

Acute Decompensated Heart Failure Forecast in 12 Major Markets 2017-2027 - Research and Markets

The "Acute Decompensated Heart Failure Forecast in 12 Major Markets 2017-2027" report has been added to Research and Markets' offering.

Acute decompensated heart failure (ADHF), a sub-set of chronic heart failure (CHF), is a life-threatening episode during which the heart is not able to supply sufficient blood flow to the body. This requires urgent medical attention. The condition is divided into two subtypes: ADHF with reduced (ADHF-REF) and preserved (ADHF-PEF) ejection fraction. HF is characterized by dyspnoea at rest or on exertion and worsening fluid retention, apparent as lung congestion and/or swollen ankles and legs.

This report provides the current prevalent population for ADHF across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Japan, China, Russia, Brazil, India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, ADHF-REF and ADHF-PEF patients have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. Moreover, a forecast of ADHF patient populations demonstrating main comorbidities has been included.

Main co-morbidities for ADHF include:

  • Diabetes
  • COPD
  • Anaemia
  • Atrial fibrillation
  • Coronary artery disease

Key Topics Covered:

1. Introduction

©2017 Morningstar Advisor. All right reserved.